The Hindu Business Line : Natco launches breast cancer drug

Natco Pharma Ltd has launched Exemestane, a niche product used in the treatment of breast cancer, under the brand name Xtane. Available as 25 mg tablets, Exemestane is used in the treatment of breast cancer of post-menopausal women who respond to hormonal therapy and are Hormone Receptor positive, according to a release.

"The product will be sold in the Indian market initially at Rs 1,290 per 30 tablets. It will be a stable and economic option to Hormone Receptor positive patients who are expected to take this medicine for a minimum period of two years,'' Mr M. Adinarayana, General Manager, Corporate Affairs, Natco, told Business Line. Being the first generic launch of Exemestane, Xtane is priced at around 1/6th of the price of the innovators brand i, he added. - Our Bureau

More Stories on : New Products & Services | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Westside to roll out Kidswest nationally

Nautica addresses price gaps to woo buyers

Hind Unilever inks ad deal with 9X

Raymond to enter readymade garments

Medical services accreditation workshop in Mumbai

A deluge of patent applications, but only 400 cleared

Marquees make a bold statement

Toys on wheels

Samsung unveils Metal 5 here

Force Motors launches two models in AP

GE Health launches new ultrasound systems

Natco launches breast cancer drug